Paclitaxel (Taxol) treatment for refractory ovarian cancer: phase II clinical trial.
OBJECTIVE
Our aim was to determine the efficacy and toxicity of paclitaxel in the treatment of refractory and platinum-resistant epithelial ovarian cancer.


METHODS
Eligibility required three prior failed chemotherapy regimens and documented platinum resistance. One hundred patients with advanced ovarian cancer received paclitaxel 135 mg/m2 over 24 hours every 21 days with optional granulocyte colony-stimulating factor support.


RESULTS
Paclitaxel was generally well tolerated. In four patients bowel perforation or fistula developed. After three cycles 34% of patients had stable disease and 25% of patients demonstrated a response, either partial or complete. After six cycles 24% of patients continued to respond. To date, six patients have achieved a complete response.


CONCLUSIONS
A 25% response rate in patients with refractory ovarian cancer was observed, which was durable to six cycles.
Seewaldt
V L
VL
Department of Medicine, University of Washington Medical Center 98155.
Greer
B E
BE
Cain
J M
JM
Figge
D C
DC
Tamimi
H K
HK
Brown
W S
WS
Miller
S A
SA
D000368:Aged; D005260:Female; D006801:Humans; D008875:Middle Aged; D010051:Ovarian Neoplasms / Q000188:drug therapy*; D017239:Paclitaxel / Q000009:adverse effects / Q000627:therapeutic use*; D012074:Remission Induction; D016896:Treatment Outcome
D017239:Paclitaxel